Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS
NCT00002643Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 1995
- Primary completion
- Jun 2003
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Covalent Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of topotecan, amifostine, filgrastim, vincristine, doxorubicin and 3 more in Ewing sarcoma and primitive neuroectodermal tumor (PNET), sponsored by National Cancer Institute. Started Apr 1995; status: completed.
02
Drugs
topotecanamifostinefilgrastimvincristinedoxorubicin
03
Conditions
Ewing sarcomaprimitive neuroectodermal tumor (PNET)
Beyond the preview
Go deeper on NCT00002643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002643.